Drug Type Antisense oligonucleotides |
Synonyms SYF2(AcuraStem) |
Target |
Mechanism SYF2 inhibitors(SYF2 pre-mRNA splicing factor inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | Preclinical | US | Acurastem, Inc.Startup | 26 Jun 2024 |
Frontotemporal Dementia | Preclinical | US | Acurastem, Inc.Startup | 26 Jun 2024 |